<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F2445869-1429-4EDE-8892-39A2D4313022"><gtr:id>F2445869-1429-4EDE-8892-39A2D4313022</gtr:id><gtr:name>Institute of Biology and Chemistry of Proteins (IBCP)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CFA47428-36B9-43F1-A098-71C95C3D7474"><gtr:id>CFA47428-36B9-43F1-A098-71C95C3D7474</gtr:id><gtr:name>STOP-HCV</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2F6044B9-9BC3-4ABA-9115-6AA15854A44A"><gtr:id>2F6044B9-9BC3-4ABA-9115-6AA15854A44A</gtr:id><gtr:name>University of Basel</gtr:name><gtr:address><gtr:line1>Petersplatz 1</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D545C73D-780E-4D1A-B5CD-1D6630A8CCCA"><gtr:id>D545C73D-780E-4D1A-B5CD-1D6630A8CCCA</gtr:id><gtr:name>Royal London Hospital</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F2445869-1429-4EDE-8892-39A2D4313022"><gtr:id>F2445869-1429-4EDE-8892-39A2D4313022</gtr:id><gtr:name>Institute of Biology and Chemistry of Proteins (IBCP)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CFA47428-36B9-43F1-A098-71C95C3D7474"><gtr:id>CFA47428-36B9-43F1-A098-71C95C3D7474</gtr:id><gtr:name>STOP-HCV</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2F6044B9-9BC3-4ABA-9115-6AA15854A44A"><gtr:id>2F6044B9-9BC3-4ABA-9115-6AA15854A44A</gtr:id><gtr:name>University of Basel</gtr:name><gtr:address><gtr:line1>Petersplatz 1</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D545C73D-780E-4D1A-B5CD-1D6630A8CCCA"><gtr:id>D545C73D-780E-4D1A-B5CD-1D6630A8CCCA</gtr:id><gtr:name>Royal London Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F1AEDFDC-82C6-4623-9593-D806A4E884BE"><gtr:id>F1AEDFDC-82C6-4623-9593-D806A4E884BE</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>McLauchlan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FD4FAE5E-DF64-432D-9924-15655316696B"><gtr:id>FD4FAE5E-DF64-432D-9924-15655316696B</gtr:id><gtr:firstName>Arvind</gtr:firstName><gtr:otherNames>H</gtr:otherNames><gtr:surname>Patel</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12014%2F1"><gtr:id>09351C63-CB80-4156-AF53-924BA9078F47</gtr:id><gtr:title>The factors that drive HCV evolution and development of an antibody-focused prophylactic HCV vaccine</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12014/1</gtr:grantReference><gtr:abstractText>HCV vaccine
Dr John McLauchlan and Dr Arvind Patel, Lead Investigators, and Dr Emma Thomson as a Co-Investigator, MRC-University of Glasgow Centre for Virus Research (CVR), University of Glasgow.
Hepatitis C virus (HCV) is passed on through blood-to-blood contact and infects the liver. In most cases, after initial infection, it remains in the blood and the liver unless those who are infected receive treatment to clear the virus. Over a long period, up to 10-20 years after infection, liver disease can develop which may lead to liver failure or cancer. Since infection is not always obvious, people are frequently unaware that they carry the virus. As a result, HCV infection is a global clinical problem; in the UK, there are up to 215,000 infected people but only about half of them have been diagnosed.
Our programme aims to understand how HCV changes in people who are infected. This is important because some people can develop resistance to the drugs used to treat the virus. Currently, there are new but expensive drugs available to cure infection. However, not everyone responds because they become resistant. We are trying to understand what changes occur in the virus to make people resistant and why these changes happen. In addition, we believe that eradicating HCV needs a vaccine, especially for poor countries that cannot afford drugs. Therefore, we are also looking at the antibodies which are naturally produced during infection to make a vaccine that would protect people from the virus.</gtr:abstractText><gtr:technicalSummary>HCV will remain a serious healthcare burden for the foreseeable future and despite attempts at intervention, new infections will persist, particularly in the 'people who inject drugs' (PWID) group. Emergence of antiviral resistance that could be transmitted in the community, and the impact of the inherent diversity within and between HCV genotypes on patient treatment are crucial challenges. In addition, virus evolution occurs in a genetically diverse host background, ultimately shaping response to infection. Fundamental questions on the contribution of host factors to pathogenesis and their role in determining the outcome of DAA therapy need to be addressed for those who fail to clear virus. Our core objective is to tackle viral evolution and host response as interconnected issues. We have developed initiatives and expertise which are central to our plans. To translate our research findings for clinical benefit, we will capitalize on HCV Research UK as a unique resource for clinical data and samples and utilize next generation sequencing (NGS) and bioinformatics pipelines to determine the evolution of viral resistance in those who do not respond to therapy. In addition, creation of gene knockouts by CRISPR technology combined with single cell sequencing will be pivotal for understanding the contribution of host factors as drivers of viral diversity, including DAA-resistance. Our future programme thus encompasses clinical to fundamental research, populations to single cells, incorporating in vivo, in vitro and in silico dimensions.
In the same vein, we set out a strategic plan for the rational design of a HCV vaccine from our studies on neutralising antibodies. Virus eradication will not succeed through antiviral therapy alone due to lack of availability and cost, and resistance may be problematic. Our aim is to isolate unique antibodies from niche patient cohorts from HCV Research UK that are otherwise difficult to access. Again, our objectives are rooted in extensive expertise allied to the benefits of core-funded sequencing platforms and cognate bioinformatics expertise. Moreover, the collaborative network established with a range of disciplines will energise the plans and bring unique ideas to confront the obstacles preventing vaccine development.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-05-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>2875000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>STOP-HCV</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>STOP-HCV</gtr:description><gtr:id>11BD9877-8074-4FDB-9346-795BCCBB4E84</gtr:id><gtr:impact>Integrated studies on viral and host genetics.</gtr:impact><gtr:outcomeId>56dd5c9e4ab366.20193874-1</gtr:outcomeId><gtr:partnerContribution>Sharing of know-how and data on viral sequencing and host genotyping.</gtr:partnerContribution><gtr:piContribution>Provision of data and samples from HCV Research UK to STOP-HCV; sharing of know-how and data in viral sequeincing and host genotyping.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of St Andrews</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biology</gtr:department><gtr:description>ISG15 cell line collaboration</gtr:description><gtr:id>D91EFD53-CD69-4CD4-BF92-614565063304</gtr:id><gtr:impact>No outputs as yet.</gtr:impact><gtr:outcomeId>58c1e515879a31.12644533-1</gtr:outcomeId><gtr:partnerContribution>Use of the cell lines to study virus infection in ISG15 knockout cell lines.</gtr:partnerContribution><gtr:piContribution>Provision of knockout cell lines for studies on ISG15</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Biology and Chemistry of Proteins (IBCP)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>IBCP</gtr:description><gtr:id>578A34B3-9198-46F2-BC69-07AB209D0FC3</gtr:id><gtr:impact>This interaction gave rise to a publication (Oehler et al in the publication list).</gtr:impact><gtr:outcomeId>89A4D37D88E-1</gtr:outcomeId><gtr:partnerContribution>IBCP is an institute that carries out NMR studies on proteins. Through a longstanding collaboration with the group, we have determined the structure of the HCV signal peptide that is a substrate for signal peptide peptidase. This would represent the first example of a structure for a substrate for this protease. The group at IBCP also have a protein synthesis facility that has prepared a synthetic substrate for SPP</gtr:partnerContribution><gtr:piContribution>My team performs all analysis of mutant signal peptides to design suitable synthetic peptides that may be substrates for signal peptide peptidase. We test these mutant signal peptides in various systems to establish their ability to be cleaved by the enzyme</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal London Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Determining resistance to all-oral DAAs using in vitro systems</gtr:description><gtr:id>D5E896ED-EF37-4149-B8AF-3A45C43633A9</gtr:id><gtr:impact>The collaboration has given rise to oral and poster presentations at national and international conferences.</gtr:impact><gtr:outcomeId>58c1e75abc7208.28626135-1</gtr:outcomeId><gtr:partnerContribution>The Royal London has carried out the in vitro studies in the project.</gtr:partnerContribution><gtr:piContribution>My group has provided HCV sequence data to direct the in vitro studies at the Royal London.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cambridge Institute for Medical Research (CIMR)</gtr:department><gtr:description>Impact of TRC8 on HCV RNA replication</gtr:description><gtr:id>50CDB239-8FBA-4F33-B591-BCC49920CC1B</gtr:id><gtr:impact>As yet there are no publications arising from the collaboration but the preliminary data are potentially exciting and could lead to longer term links with Prof Lehner's group in Cambridge.</gtr:impact><gtr:outcomeId>ARrN1Pj67Z8-1</gtr:outcomeId><gtr:partnerContribution>We have established a collaboration with a group at CIMR in Cambridge who study the role of ubiquitin ligases in virus infection. The link has expanded the range of studies in which we are engaged on interactions between HCV and cellular processes.</gtr:partnerContribution><gtr:piContribution>My group provides the systems for analysis of HCV RNA replication and production of infectious virus.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Basel</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Department of Biomedicine</gtr:department><gtr:description>University of Basel</gtr:description><gtr:id>A22F0CE5-0793-4D86-8B16-74D398448E88</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>58bea5f43e3da6.18991990-1</gtr:outcomeId><gtr:partnerContribution>Our partners have provided unique frozen, unfixed biopsies for our single cell transcriptomic studies. They have also provided clinical and molecular data related to the biopsies that is critical for interpreting our data.</gtr:partnerContribution><gtr:piContribution>My team is making use of liver biopsies to study single cell transcriptomics by laser microdissection.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>C McCormick, University of Southampton</gtr:description><gtr:id>4DCCF563-C56F-4462-BD8B-A8EB2D3240C2</gtr:id><gtr:impact>Collaboration has given rise to 1 publication with more in the pipeline. Collaborator also submitted a grant application to MRC (unsuccessful).</gtr:impact><gtr:outcomeId>54639f47615bc3.10500248-1</gtr:outcomeId><gtr:partnerContribution>Partner developed a novel system for examining HCV RNA replication using subgenomic replicons</gtr:partnerContribution><gtr:piContribution>Studies on the mechanism of HCV RNA replication</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MRC Insight Publication</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F4B6EA09-5900-4DB5-8DDC-158A30C2C702</gtr:id><gtr:impact>Blog for MRC Insight to update activities associated with HCV Research UK and STOP-HCV.</gtr:impact><gtr:outcomeId>58c1ea1fd8f555.69497246</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.insight.mrc.ac.uk/2015/07/28/finding-the-right-treatment-for-patients-with-hepatitis-c/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC News Story - HCV Alert Carol Leitch 23 February 2016</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>00A305B1-7653-45F3-A9FB-2FF1BA1E7EFD</gtr:id><gtr:impact>Carol Leitch, at the request of Health Protection Scotland carried out the phylogenetic analysis of the 2 patient samples suspected of being infected by a healthcare worker in Lanarkshire. She was able to show that the HCV infecting these individuals was closely related and this was backed up by individuals from PHE who performed another analysis. This led to the realisation that these patients had likely been infected during a procedure carried out by the healthcare worker. This information formed the basis of a report submitted by NHS Lanarkshire to the UK Advisory Panel for Healthcare Workers Infected with Blood Borne Viruses and the national body endorsed the health board's proposal to carry out a patient notification exercise. 8383 patients treated by this healthcare worked will now be contacted and offered screening for HCV. As a result, the BBC featured a news story about the security alert- http://www.bbc.co.uk/news/uk-scotland-glasgow-west-35639826. This is an example how the work of the CVR has a direct influence on Policy, Practice, along with patients and public interests.</gtr:impact><gtr:outcomeId>56ced718a5e373.28485475</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>https://www.facebook.com/centreforvirusresearch/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CVR Blog post 1: Hepatitis C Virus (Connor Bamford) - February 2015</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0346F64B-54CD-4083-9640-AA29F388D1DE</gtr:id><gtr:impact>The blog post encouraged online comments and discussion among readers.

The post encouraged readers to follow the CVR blog therefore encouraging further future interaction and engagement.</gtr:impact><gtr:outcomeId>569784aba0ac49.28398553</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>https://www.facebook.com/centreforvirusresearch/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Kelvingrove Museum Science Weekend</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>645D6F83-4FDE-4D1F-BAB2-3F0E69D0BE68</gtr:id><gtr:impact>We ran our 'Build a virus' and 'One Infection' activities - offering participants the opportunity to learn all about the structure of viruses and also key messages related to the transmission of viruses, hygiene and vaccination.

Participants were asked to provide feedback on the activities to help us determine how to improve the activity in future. We have been asked to submit a proposal to run an activity during the Glasgow Science Festival in June 2015.</gtr:impact><gtr:outcomeId>5464785e3c7ff7.86029250</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centenary Celebrations</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6A4ECE5B-23A9-40C7-A1C0-99B587918099</gtr:id><gtr:impact>Over the course of two events in June 2013, we interacted with approximately 350 children and their families. We used these interactions to communicate some basic facts about viruses - focussing on their size, structure, routes of transmission and how to limit spread. As part of the activity, we asked participants to consider the question 'If you were a virology researcher what would you study?' and collected responses using post-it note feedback. This provided a good opportunity to discuss the impact of medical research (we often used vaccines as an example), and the importance of the support of the Medical Research Council to help scientists tackle some of the greatest health problems facing humanity.

We have been invited to display the timeline at local schools and science centres across Scotland.</gtr:impact><gtr:outcomeId>Hsgr3gyfB7e</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.virusesacenturyofdiscovery.org.uk</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Carol Monaghan MP visit - 30 October 2015</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E2AF1F33-13DE-4EC8-A92C-35DE47C997F4</gtr:id><gtr:impact>Local MP of the Glasgow North West Constituency Carol Monaghan came to visit the CVR to meet with our Director Massimo Palmarini to learn about the important research carried out at the centre along with taking in a tour of the facility. Carol was able to meet with several of our researchers who provided short presentations about their research. Carol was very enthusiastic to learn about our research, links with industry and also about importance of funding. She then went on to mention the CVR and what she had learned during the visit at a parliamentary meeting in Westminster later that week. Furthermore, she then went on to visit one of the other Biomedical research centres that forms part of the University of Glasgow to gain a further insight into some of the important work and research being carried out across the University.</gtr:impact><gtr:outcomeId>56af5ece30d339.17399789</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:url>https://www.facebook.com/centreforvirusresearch/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>National Forum for HCV</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F3856573-8C72-4A08-93E5-59EF6C6E763B</gtr:id><gtr:impact>Presented data on resistance identified in patients receiving new therapies for HCV infection to inform a national group about the possible importance of resistance testing.</gtr:impact><gtr:outcomeId>58c97544bdf2b9.08781303</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CVR Blog #12 CVR at the Glasgow Science Festival - July 2015</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F8E1B99E-DF4C-4C7B-98D8-26F0269F0A64</gtr:id><gtr:impact>Our 12th blog showcased the CVR's activities at the Glasgow Science Festival in June 2015. The post reached 792 people on Facebook and received 183 views.</gtr:impact><gtr:outcomeId>56d457958f8398.54631681</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>https://www.facebook.com/centreforvirusresearch/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Connor Bamford - The Conversation Oct 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1C3E343F-5BD7-420E-85E4-114C168F5A96</gtr:id><gtr:impact>Connor Bamford, CVR postdoc, discusses the shipment of an experimental Ebola vaccine to West Africa in a blog in The Conversation.

Due to the popularity of Connor's blogs, he is now featured as a regular writer in this popular online publication.</gtr:impact><gtr:outcomeId>54629de2169109.39474930</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://theconversation.com/high-hopes-rest-on-800-vials-of-experimental-ebola-vaccine-shipped-from-canada-33201</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Blog Post #4: Measles (Connor Bamford) - March 2015</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>84889806-0328-4701-8345-3C4C0D77AE93</gtr:id><gtr:impact>This post received 179 views along with online comments and discussion, and likes and tweets on social media.

Connor Bamford, the author of the post, received 4 emails providing positive feedback both from other CVR researchers but also from external colleagues, demonstrating that the blog was gaining further interest and was viewed in a positive light.</gtr:impact><gtr:outcomeId>569795fbaaf717.03914092</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>https://www.facebook.com/centreforvirusresearch/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Connor Bamford &amp; Andrew Shaw - The Conversation</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>636D8B5A-9CDC-4950-A122-CCC8CEB85174</gtr:id><gtr:impact>Connor Bamford &amp;amp; Andrew Shaw, CVR postdoctoral researchers, posted a blog in 'The Conversation' about the need for research on highly pathogenic viruses to continue.

Blog writing helps to promote the breadth of research carried out by the CVR and again, raises our profile while helping our researchers meet their IMPACT targets. It's a great tool that enables researchers to reach a lay audience about engaging scientific information that's currently making the news headlines.


Connor Bamford has been invited to write further blogs for The Conversation.</gtr:impact><gtr:outcomeId>546295d2a52435.32776557</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.facebook.com/centreforvirusresearch</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Scottish Society for Gastroenterology</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>252B3083-476D-4CC0-B12D-57926EBEC397</gtr:id><gtr:impact>Presented lecture on targets for new therapies for HCV infection and issues over drug resistance to clinicians at a national conference.</gtr:impact><gtr:outcomeId>58c9711d88c893.20610308</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CVR Blog #10 Viral Hepatitis - Connor Bamford July 2015</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B66FFCE4-5CE6-464F-85A1-FB01153D6661</gtr:id><gtr:impact>Our 10th blog post about Hepatitis C infection. The blog post reached 776 people on Facebook and received 563 views.</gtr:impact><gtr:outcomeId>56d45574961947.93502609</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>https://www.facebook.com/centreforvirusresearch/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hepatitis C Virus Origins Paper Press Release October 2015</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5CD04083-2903-4C8D-B4D7-D97C45E4633C</gtr:id><gtr:impact>Following the publication of a CVR paper, which demonstrated the origins of Hepatitis C virus in Scotland, we issued a press release for distribution to the media. This resulted in news stories in several news papers including The Scotsman, The Herald, The Independent and the Daily Express as well as a feature on the BBC news website. Carol Leitch (one of the authors) also took part in an interview with BBC Radio Scotland. Links to stories as follows:
http://www.bbc.co.uk/news/uk-scotland-34658098
http://www.thetimes.co.uk/tto/news/uk/scotland/article4599284.ece
http://www.scotsman.com/news/health/scientists-track-hepatitis-c-roots-in-scotland-1-3930369#axzz3pwgMI6mV
http://www.heraldscotland.com/news/homenews/13901425.Research_traces_hepatitis_C_infection_roots_to_Second_World_War/
http://www.thenational.scot/news/wartime-glasgow-study-offers-hope-in-hepatitis-c-battle.9
http://medicalxpress.com/news/2015-10-hepatitis-infections-scotland-wwii.html</gtr:impact><gtr:outcomeId>56aa34eaf3e112.55988461</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>https://www.facebook.com/centreforvirusresearch/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CVR Blog #7 Microtalks - Connor Bamford May 2015</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8CDF10D5-B60C-4515-B684-3A9C49E516F1</gtr:id><gtr:impact>Our 7th Blog post promoting a CVR Glasgow Science Festival event. Reached 131 people on Facebook and received 160 views.</gtr:impact><gtr:outcomeId>56d43b758233b7.55278812</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>https://www.facebook.com/centreforvirusresearch/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Festival of Medical Research</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CAA03243-5939-4A39-8AA0-109DDA67483C</gtr:id><gtr:impact>The event was aimed at individuals infected with hepatitis C virus (HCV) as well as carers, professionals and national support groups for those infected with the virus. The day was planned to include talks on various topics relevant to HCV-infected individuals (new treatments, likely outcomes, liver disease) and how the CVR was addressing these themes in its research portfolio. Feedback on the event was universally positive from those who attended.</gtr:impact><gtr:outcomeId>58bec5fd6be752.61332973</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sun Yat-Sen University, Guangzhou, China</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F4D35AB0-ADAF-4183-A490-69DE7428235A</gtr:id><gtr:impact>Invited lecture to promote collaboration between CVR and Sun Yat-Sen University. The outcome was a collaboration with the Guangzhou Blood Centre, which led to a 1 year working visit by a senior member of their staff to the CVR.</gtr:impact><gtr:outcomeId>58c933c31aca75.97068849</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Scotland - Report on introduction of HCV into Scotland</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BA6C448A-8CCC-4DB6-A863-A8D0E5648E33</gtr:id><gtr:impact>Media interview with BBC Scotland and release of information on BBC website.</gtr:impact><gtr:outcomeId>58c977a9c8a324.30697799</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/news/uk-scotland-34658098</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sheila Sherlock Updates, Royal Free London</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C7E75837-3F3D-4674-9070-5A7F243622B6</gtr:id><gtr:impact>Presented invited lecture on targets for new therapies for HCV infection and issues over drug resistance to clinicians and academic staff.</gtr:impact><gtr:outcomeId>58c9345b035e94.91403591</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CVR Blog #17 ADAP2 Inhibition Connor Bamford October 2015</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9BD8CBCA-FFC5-4877-A2EF-1BF0C043EDD6</gtr:id><gtr:impact>Our 17th Blog post by Connor Bamford on the topic of ADAP2 inhibition and virus entry into cells. The post was viewed 144 times.</gtr:impact><gtr:outcomeId>56d45f6e61c6a9.17875219</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>https://www.facebook.com/centreforvirusresearch/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Blog for MRC Insight - 2013</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8762D698-7995-48D5-9FF1-65B27824BF35</gtr:id><gtr:impact>Blog written for MRC Insight to describe the aims of HCV Research UK.</gtr:impact><gtr:outcomeId>58c1eb09b9a8c5.07922041</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.insight.mrc.ac.uk/2013/01/21/a-helping-hand-for-hepatitis-c-treatment/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Leicester</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>761F1BF2-0DB5-48A8-A6E1-9323574DA19F</gtr:id><gtr:impact>Presentation on how different disciplines impact on virus research.</gtr:impact><gtr:outcomeId>58c970ca5cc064.57967965</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CVR Blog Post 2: Meet the Expert Dr John Mclachlan (Veronica Rezelj) - February 2015</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2634A591-964C-4FAA-AE21-6654E028AB49</gtr:id><gtr:impact>192 people read the blog post with likes reported on Facebook and Twitter.

The increased number of views versus the first post demonstrated a heightened awareness of the blog and therefore, demonstrated an uplift in followers.</gtr:impact><gtr:outcomeId>569788c798b1e0.40016076</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>https://www.facebook.com/centreforvirusresearch/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Abbvie Medical Team</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>383367A7-F984-4543-8D2B-C81D3D7FFB39</gtr:id><gtr:impact>Organised an afternoon of speakers and presentations on a) HCV diagnostics now an din the future, b) sequencing methods for identifying resistance in patients who fail therapy and c) possible issues for difficult-to-treat patients with new therapies.</gtr:impact><gtr:outcomeId>58c974862e07e5.89186752</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2014,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICGEB meeting on Human RNA Viruses, Costa Rica</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>25F3162F-52B2-4C8B-8648-C23E5CD2CBF2</gtr:id><gtr:impact>Gave invited lecture and allowed advertising the CVR as an international centre for virological research.</gtr:impact><gtr:outcomeId>58c971f3a85221.01832126</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.icgeb.org/rna-virus-workshop-2016.html</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>194728</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UK-Philippines: Joint Health Research Call</gtr:description><gtr:end>2019-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N019245/1</gtr:fundingRef><gtr:id>E31919D5-26C3-431F-B999-AF5757FCC77A</gtr:id><gtr:outcomeId>58bec1ba835ed4.08722878</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1924918</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Medical Research Foundation</gtr:department><gtr:description>Studies on Liver Disease</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>C0365</gtr:fundingRef><gtr:id>DE9B4C6B-6F2A-4D2A-BDCF-D35E526A43E5</gtr:id><gtr:outcomeId>58bec35c5d6975.97360220</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>280852</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Stratified Medicine - STOP HCV</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A3CC9CF3-46C3-4F4B-AD13-83E02FAF371D</gtr:id><gtr:outcomeId>5464779337c8d7.93056228</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The technology enabled the enrichment of HCV-specific sequences in Next Generation Sequencing. It also increased the numbers of samples that could be included in a single sequencing run from about 10-12 to 90, which is much more cost effective.</gtr:description><gtr:id>3768BC54-F81C-4914-A5BC-8E5B2C41A1F4</gtr:id><gtr:impact>The methodology is now being developed for diagnostic services and to establish an enrichment platform for flaviviruses circulating in the Philippines.</gtr:impact><gtr:outcomeId>58c979a36cc9f2.13374236</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>NGS Target Enrichment</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The cell lines were created by CRISPR-Cas9 knockout of the ISG15 gene. This allows studies on the role of ISGylation, a post-translational event that has critical roles in regulating cellular pathways and processes.</gtr:description><gtr:id>FAD0A884-3CBF-49C4-9180-8B6AC19DA457</gtr:id><gtr:impact>Preliminary data has shown that the cells have a distinct phenotype during virus infection. This line of research is being continued by our collaborators.</gtr:impact><gtr:outcomeId>58c97ac0804a83.61766209</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Cell lines -ISG15 knockout cells</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>This methodology improved the multiplexing and depth of coverage of HCV viral sequences compared to a more fundamental approach using metagenomics. The technology was developed to allow capture of viral sequences to very low levels (only a few hundred copies of viral genomes/ml).</gtr:description><gtr:id>20D88311-3280-46CC-8B82-94F0720C6E17</gtr:id><gtr:impact>The approach is now being introduced to Public Health England for their diagnostic service to detect and identify HCV sequences.</gtr:impact><gtr:outcomeId>58bec952541749.45132523</gtr:outcomeId><gtr:title>Target Enrichment for HCV Genomics</gtr:title><gtr:type>New/Improved Technique/Technology</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>136B56F5-57A3-4EA6-A0A9-7C0468AC23AC</gtr:id><gtr:title>Hepatitis C Virus-Induced Degradation of Cell Death-Inducing DFFA-Like Effector B Leads to Hepatic Lipid Dysregulation.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7212f493bb337c6ce321209931460c89"><gtr:id>7212f493bb337c6ce321209931460c89</gtr:id><gtr:otherNames>Lee EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>56dd549999b1a5.96501888</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>121C0919-99A5-4844-97E5-B24DFA9AA3A9</gtr:id><gtr:title>Non cell autonomous upregulation of CDKN2 transcription linked to progression of chronic hepatitis C disease.</gtr:title><gtr:parentPublicationTitle>Aging cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff1ce01119437413e50c82aebe529290"><gtr:id>ff1ce01119437413e50c82aebe529290</gtr:id><gtr:otherNames>Robinson MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-9718</gtr:issn><gtr:outcomeId>pm_14590_20_23931242</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C718F300-7B82-4571-B546-90A9E260E2E8</gtr:id><gtr:title>Determining the cellular diversity of hepatitis C virus quasispecies by single-cell viral sequencing.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb04c8328cd570b159c2b5c170c81045"><gtr:id>bb04c8328cd570b159c2b5c170c81045</gtr:id><gtr:otherNames>McWilliam Leitch EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_14590_20_24049174</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC9B9D6D-E92B-4BB3-A46F-5E3B46DD2B49</gtr:id><gtr:title>Polyprotein-Driven Formation of Two Interdependent Sets of Complexes Supporting Hepatitis C Virus Genome Replication.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1007177b070fd8948f81a739a5a8cef"><gtr:id>c1007177b070fd8948f81a739a5a8cef</gtr:id><gtr:otherNames>Gomes RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>56dd5393aacfb4.72828032</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53FC951D-78F6-4861-A05D-D9C8331DC80C</gtr:id><gtr:title>Mobility analysis of an NS5A-GFP fusion protein in cells actively replicating hepatitis C virus subgenomic RNA.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f4d25b6669299e48eaa57afb7ff449e"><gtr:id>4f4d25b6669299e48eaa57afb7ff449e</gtr:id><gtr:otherNames>Jones DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>10733DF2C4C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A985DE2-9007-40C2-979A-CFAACD433095</gtr:id><gtr:title>Comparison of U2OS and Huh-7 cells for identifying host factors that affect hepatitis C virus RNA replication.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f4d25b6669299e48eaa57afb7ff449e"><gtr:id>4f4d25b6669299e48eaa57afb7ff449e</gtr:id><gtr:otherNames>Jones DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>fCa1VHcw5vz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C0D9FAA-6E78-4578-A117-018E70EBD8AC</gtr:id><gtr:title>Inhibition of hepatitis C virus RNA replication by ISG15 does not require its conjugation to protein substrates by the HERC5 E3 ligase.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94637bff243aa9846abef2209ac3fbd0"><gtr:id>94637bff243aa9846abef2209ac3fbd0</gtr:id><gtr:otherNames>Domingues P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>56dd539313f408.35745803</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BCCC63E-214F-4AFC-AABB-C89DE9F8AADD</gtr:id><gtr:title>Efficient cleavage by signal peptide peptidase requires residues within the signal peptide between the core and E1 proteins of hepatitis C virus strain J1.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40932adf1e5a3e701095af61f65def52"><gtr:id>40932adf1e5a3e701095af61f65def52</gtr:id><gtr:otherNames>Hope RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>ED66F5A2BFF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E0106D3-3BFB-436B-9682-74A208FE751F</gtr:id><gtr:title>Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa56070c948c0fb966fe86c46b8bd5f7"><gtr:id>aa56070c948c0fb966fe86c46b8bd5f7</gtr:id><gtr:otherNames>Foster GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>56dd53f425e378.14003971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5F065AD-2900-4B39-AEAC-582B6785DFFA</gtr:id><gtr:title>Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c459be330ceaf8f5dd44bbde4d600ce"><gtr:id>3c459be330ceaf8f5dd44bbde4d600ce</gtr:id><gtr:otherNames>Swann RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>56dd5499c5fd82.51285939</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29B70129-0F40-4024-88E0-C29DCC207263</gtr:id><gtr:title>Lipid droplets and hepatitis C virus infection.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a8c3bb19afe31ed1202a22f36057dcc"><gtr:id>6a8c3bb19afe31ed1202a22f36057dcc</gtr:id><gtr:otherNames>McLauchlan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>8015A8EA39E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D85EF68-E39B-4D16-8557-4ADD97BE2989</gtr:id><gtr:title>Signal peptide peptidase cleavage of GB virus B core protein is required for productive infection in vivo.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52ca551475cb45046074c8ac9c17889d"><gtr:id>52ca551475cb45046074c8ac9c17889d</gtr:id><gtr:otherNames>Targett-Adams P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>63F2567F3C5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>493E4269-8153-4DEB-B78C-47D759B96BC1</gtr:id><gtr:title>The lipid droplet binding domain of hepatitis C virus core protein is a major determinant for efficient virus assembly.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be36d06c89f5a15ffd33bd64c8554099"><gtr:id>be36d06c89f5a15ffd33bd64c8554099</gtr:id><gtr:otherNames>Shavinskaya A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>E9A017927DA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66E7D108-85C2-4A26-AC27-42634BED5442</gtr:id><gtr:title>Modulation of triglyceride and cholesterol ester synthesis impairs assembly of infectious hepatitis C virus.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a0c9b3a83ab1f5c64a9269bb2366429"><gtr:id>9a0c9b3a83ab1f5c64a9269bb2366429</gtr:id><gtr:otherNames>Liefhebber JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>545a56b7a30118.71638802</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>490C2377-93F1-44E5-B1CA-B5E9B2FD8293</gtr:id><gtr:title>Full Genome Sequence and sfRNA Interferon Antagonist Activity of Zika Virus from Recife, Brazil.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8f028a0beb9437345f8ec909e45a6cb"><gtr:id>e8f028a0beb9437345f8ec909e45a6cb</gtr:id><gtr:otherNames>Donald CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>5aa64c6d785022.44426533</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF694290-AD18-4043-8D52-417DFEED8D21</gtr:id><gtr:title>Viral genotype correlates with distinct liver gene transcription signatures in chronic hepatitis C virus infection.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff1ce01119437413e50c82aebe529290"><gtr:id>ff1ce01119437413e50c82aebe529290</gtr:id><gtr:otherNames>Robinson MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn><gtr:outcomeId>5675e13dc04ad</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFA1A3E8-18A7-4386-A169-BC36314CFCEF</gtr:id><gtr:title>Hepatitis C Virus NS5A Targets Nucleosome Assembly Protein NAP1L1 To Control the Innate Cellular Response.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a6010e033d0ba08199ad78674df8bf1"><gtr:id>4a6010e033d0ba08199ad78674df8bf1</gtr:id><gtr:otherNames>?evik RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5aa64c33919329.30824865</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>462849C9-C711-4FCC-A54D-A9A7FD8EC4C3</gtr:id><gtr:title>Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries</gtr:title><gtr:parentPublicationTitle>JOURNAL OF HEPATOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa2971e0e0517f675e1dbcc45b7c3eb2"><gtr:id>fa2971e0e0517f675e1dbcc45b7c3eb2</gtr:id><gtr:otherNames>Filipe Ana da Silva</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>5a34ec6054d3e7.39622038</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51A0EC28-02EC-474C-A43C-BD5D5F7BEB72</gtr:id><gtr:title>The Mechanism of Interferon Refractoriness During Hepatitis C Virus Infection and Its Reversal with a Peroxisome Proliferator-Activated Receptor a Agonist.</gtr:title><gtr:parentPublicationTitle>Journal of interferon &amp; cytokine research : the official journal of the International Society for Interferon and Cytokine Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4af9d2ae0246ed3e6c716a42d000dec7"><gtr:id>4af9d2ae0246ed3e6c716a42d000dec7</gtr:id><gtr:otherNames>Read SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1079-9907</gtr:issn><gtr:outcomeId>56dd5393dfd7d9.54073686</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CD5F84C-31B0-4575-BAA3-D40636BCCC27</gtr:id><gtr:title>Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/640066d44c0c0ff681f127fcc480dff3"><gtr:id>640066d44c0c0ff681f127fcc480dff3</gtr:id><gtr:otherNames>Cheung MCM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>589ddb07398eb2.25251183</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F0C7357-68FC-462E-A303-BDA4FCA71279</gtr:id><gtr:title>Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6f99873305a936fa678a502a79cfe16"><gtr:id>a6f99873305a936fa678a502a79cfe16</gtr:id><gtr:otherNames>Angus AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>545a57bea4cee6.96787704</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C531359A-3AD3-49ED-846C-E43161B67A04</gtr:id><gtr:title>Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a8c3bb19afe31ed1202a22f36057dcc"><gtr:id>6a8c3bb19afe31ed1202a22f36057dcc</gtr:id><gtr:otherNames>McLauchlan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>5a34ec6dd2caa7.41692734</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC1C69E7-BA4E-4004-8570-0A4502A37209</gtr:id><gtr:title>Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f910cfd938f25e6e6e45c466f2c7dc1"><gtr:id>1f910cfd938f25e6e6e45c466f2c7dc1</gtr:id><gtr:otherNames>Ansari MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5a34ec8c8e21e3.70856101</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F31F8CCF-30F6-418A-BAF5-DC8606D5CAC3</gtr:id><gtr:title>Functional characterization of core genes from patients with acute hepatitis C virus infection.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b784cfc64594123078dc67f487d27391"><gtr:id>b784cfc64594123078dc67f487d27391</gtr:id><gtr:otherNames>Tang X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>gJMNTMBLJuW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C83D19F-B97B-460A-8573-0FB7970AF134</gtr:id><gtr:title>Hepatitis C virus: assembly and release of virus particles.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f4d25b6669299e48eaa57afb7ff449e"><gtr:id>4f4d25b6669299e48eaa57afb7ff449e</gtr:id><gtr:otherNames>Jones DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>DDWwSfsHzrq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3825FA6A-931C-474B-8EA3-0020B1E7AD87</gtr:id><gtr:title>Disrupting the association of hepatitis C virus core protein with lipid droplets correlates with a loss in production of infectious virus.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1793744db38f8a6171fc453edf6fa11b"><gtr:id>1793744db38f8a6171fc453edf6fa11b</gtr:id><gtr:otherNames>Boulant S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>4285C69D23B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46B52F60-9D6D-453F-A3A8-A9D425A846D8</gtr:id><gtr:title>Maturation of hepatitis C virus core protein by signal peptide peptidase is required for virus production.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52ca551475cb45046074c8ac9c17889d"><gtr:id>52ca551475cb45046074c8ac9c17889d</gtr:id><gtr:otherNames>Targett-Adams P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>FF2898E14C9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF7266AA-FD1F-4B4F-B1B4-0A13090E75C3</gtr:id><gtr:title>Bidirectional lipid droplet velocities are controlled by differential binding strengths of HCV core DII protein.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d201b2d848c8443b39f6f7e4933e2d42"><gtr:id>d201b2d848c8443b39f6f7e4933e2d42</gtr:id><gtr:otherNames>Lyn RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>545a5618bb13d0.85379754</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09A7E704-D427-49DE-8B4E-E893E8CDE68C</gtr:id><gtr:title>The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f4d25b6669299e48eaa57afb7ff449e"><gtr:id>4f4d25b6669299e48eaa57afb7ff449e</gtr:id><gtr:otherNames>Jones DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>9A8FF8B3586</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC166422-062B-4C15-835F-17A54DD44515</gtr:id><gtr:title>Spatiotemporal Reconstruction of the Introduction of Hepatitis C Virus into Scotland and Its Subsequent Regional Transmission.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1781f91e10a76951f7b9697566b072de"><gtr:id>1781f91e10a76951f7b9697566b072de</gtr:id><gtr:otherNames>McNaughton AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5675eac99ef8f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07DB39ED-E959-4459-812E-D8EBC61BAEEF</gtr:id><gtr:title>Hepatitis C virus: viral proteins on the move.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a8c3bb19afe31ed1202a22f36057dcc"><gtr:id>6a8c3bb19afe31ed1202a22f36057dcc</gtr:id><gtr:otherNames>McLauchlan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>E589D32F276</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A416265-882E-4CAE-8F19-91CEED126271</gtr:id><gtr:title>Hepatitis C virus and lipid droplets: finding a niche.</gtr:title><gtr:parentPublicationTitle>Trends in molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1adb0e817ae4fde2191a701364e92d1"><gtr:id>c1adb0e817ae4fde2191a701364e92d1</gtr:id><gtr:otherNames>Filipe A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-4914</gtr:issn><gtr:outcomeId>5aa64d1c77c310.36000487</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>404668FE-8BD2-4625-ADEB-20011070445F</gtr:id><gtr:title>Initiation of hepatitis C virus infection requires the dynamic microtubule network: role of the viral nucleocapsid protein.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8630b5e1b642f63abe0854dff737976"><gtr:id>e8630b5e1b642f63abe0854dff737976</gtr:id><gtr:otherNames>Roohvand F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>47B57BEF00E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66638CE9-0287-4CEC-831D-92B2BDD32224</gtr:id><gtr:title>Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cc1a629d431ece4a70f4e2339867e5a"><gtr:id>4cc1a629d431ece4a70f4e2339867e5a</gtr:id><gtr:otherNames>da Silva Filipe A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>5a661667d25df5.16928953</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E71E21D-B837-4D65-A093-89C9979CA0DA</gtr:id><gtr:title>Subcellular localizations of the hepatitis C virus alternate reading frame proteins.</gtr:title><gtr:parentPublicationTitle>Virus research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b6851dd2a0911ed2113582cb7ab736e"><gtr:id>0b6851dd2a0911ed2113582cb7ab736e</gtr:id><gtr:otherNames>Ratinier M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0168-1702</gtr:issn><gtr:outcomeId>02BFDB0D004</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45E665F6-53FC-4717-AEA3-0DCE6654C3E2</gtr:id><gtr:title>Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7824c6b884f13b2d24d23c50b62df18f"><gtr:id>7824c6b884f13b2d24d23c50b62df18f</gtr:id><gtr:otherNames>Benga WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>bjPZXD4DZkq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA28E0AA-D518-4447-92BF-D00B94359310</gtr:id><gtr:title>Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f184e1a5169e970ee2668a72321eb0c"><gtr:id>2f184e1a5169e970ee2668a72321eb0c</gtr:id><gtr:otherNames>Thomson E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>588b612f2608f2.46199024</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF20C3FA-447D-4D30-BFC1-701CCB9646D2</gtr:id><gtr:title>Genetic complementation of hepatitis C virus nonstructural protein functions associated with replication exhibits requirements that differ from those for virion assembly.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f91ecfe62149449f8632ab22b64ba6e"><gtr:id>7f91ecfe62149449f8632ab22b64ba6e</gtr:id><gtr:otherNames>Herod MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>545a55e8206277.23597171</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CA868A9-C5F2-4A2C-8D72-33C75BFBBC5C</gtr:id><gtr:title>Tracking TCR? Sequence Clonotype Expansions during Antiviral Therapy Using High-Throughput Sequencing of the Hypervariable Region.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff1ce01119437413e50c82aebe529290"><gtr:id>ff1ce01119437413e50c82aebe529290</gtr:id><gtr:otherNames>Robinson MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5aa64cec37d358.75000202</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1704D56-070D-4B45-B939-45D355D6B6BB</gtr:id><gtr:title>Increasing rate of cleavage at boundary between non-structural proteins 4B and 5A inhibits replication of hepatitis C virus.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f91ecfe62149449f8632ab22b64ba6e"><gtr:id>7f91ecfe62149449f8632ab22b64ba6e</gtr:id><gtr:otherNames>Herod MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_14590_20_22084249</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0C064C1-F092-4345-90E9-4909B33BAA8D</gtr:id><gtr:title>Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/222b0ea5d8256a7d1e15a75909fd789a"><gtr:id>222b0ea5d8256a7d1e15a75909fd789a</gtr:id><gtr:otherNames>Abdelrahman T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>545a56b7c8edc7.61667162</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BA181C6-30F4-4CE0-B180-78A0A25C4738</gtr:id><gtr:title>Structural determinants that target the hepatitis C virus core protein to lipid droplets.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1793744db38f8a6171fc453edf6fa11b"><gtr:id>1793744db38f8a6171fc453edf6fa11b</gtr:id><gtr:otherNames>Boulant S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>9EAF68F08D6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62A2CEE6-8EC5-4DF6-B689-F548AF6A7676</gtr:id><gtr:title>Fluorescence lifetime imaging of alterations to cellular metabolism by domain 2 of the hepatitis C virus core protein.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a14676baaf8f7a2023c2b9f50efa27d"><gtr:id>6a14676baaf8f7a2023c2b9f50efa27d</gtr:id><gtr:otherNames>Mazumder N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14590_20_23826122</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC24F254-6ABB-47A0-A2C2-319C537A3AC3</gtr:id><gtr:title>Elevated interferon-stimulated gene transcription in peripheral blood mononuclear cells occurs in patients infected with genotype 1 but not genotype 3 hepatitis C virus.</gtr:title><gtr:parentPublicationTitle>Journal of viral hepatitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff1ce01119437413e50c82aebe529290"><gtr:id>ff1ce01119437413e50c82aebe529290</gtr:id><gtr:otherNames>Robinson MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1352-0504</gtr:issn><gtr:outcomeId>545a56b77e5408.19538307</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34FD876B-1F26-4AC1-9AA8-E1BA068F2FAB</gtr:id><gtr:title>Hepatitis C virus core protein induces lipid droplet redistribution in a microtubule- and dynein-dependent manner.</gtr:title><gtr:parentPublicationTitle>Traffic (Copenhagen, Denmark)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1793744db38f8a6171fc453edf6fa11b"><gtr:id>1793744db38f8a6171fc453edf6fa11b</gtr:id><gtr:otherNames>Boulant S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1398-9219</gtr:issn><gtr:outcomeId>D5A10461BA6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC36D2CB-3454-436D-A99B-F7E6942D088E</gtr:id><gtr:title>Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbbd64fcd1ea78c405e06d38e7028ccc"><gtr:id>dbbd64fcd1ea78c405e06d38e7028ccc</gtr:id><gtr:otherNames>Felmlee DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>iTkx5tPshKq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6562414F-E1E5-4125-8E7B-397828B200E3</gtr:id><gtr:title>Visualization of double-stranded RNA in cells supporting hepatitis C virus RNA replication.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52ca551475cb45046074c8ac9c17889d"><gtr:id>52ca551475cb45046074c8ac9c17889d</gtr:id><gtr:otherNames>Targett-Adams P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>8C129472DF1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>524F0C39-5269-4077-B6EC-4333B260A9A4</gtr:id><gtr:title>Reply: To PMID 24797101.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/222b0ea5d8256a7d1e15a75909fd789a"><gtr:id>222b0ea5d8256a7d1e15a75909fd789a</gtr:id><gtr:otherNames>Abdelrahman T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>545a56b7ef9509.26568898</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1063C1EA-30FA-4707-93C3-C2B9B2393E40</gtr:id><gtr:title>Transcriptional slippage prompts recoding in alternate reading frames in the hepatitis C virus (HCV) core sequence from strain HCV-1.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b6851dd2a0911ed2113582cb7ab736e"><gtr:id>0b6851dd2a0911ed2113582cb7ab736e</gtr:id><gtr:otherNames>Ratinier M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>2D7BE74CD75</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07A14F57-45AA-4AE4-B0AD-8FC7E08C0E0B</gtr:id><gtr:title>Lipid metabolism and HCV infection.</gtr:title><gtr:parentPublicationTitle>Viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52ca551475cb45046074c8ac9c17889d"><gtr:id>52ca551475cb45046074c8ac9c17889d</gtr:id><gtr:otherNames>Targett-Adams P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1999-4915</gtr:issn><gtr:outcomeId>pm_14590_20_21994676</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12014/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>